Heart failure: The frequent, forgotten, and often fatal complication of diabetes

Diabetes Care

Volumn 26, Issue 8, 2003, Pages 2433-2441

  Bell, David S H ^a,b  

^a University of Alabama at Birmingham   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; METOPROLOL; PROPRANOLOL; TIMOLOL;

ADRENERGIC SYSTEM; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG USE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORTALITY; PROGNOSIS; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VASOCONSTRICTION;

DIABETES COMPLICATIONS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0043025552     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.8.2433     Document Type: Review

References (98)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
2. Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:1614-1619, 2001
3. Aronow WS, Ahn C: Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 115:867-868, 1999
4. Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, Varricchio M, Rengo F: Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly: the Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23:213-218, 1997
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
6. Reis SE, Holubkov R, Edmundowicz D, McNamara DM, Zell KA, Detre KM, Feldman AM: Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 30:733-738, 1997
7. Bell DSH, Ovalle F: Frequency of diabetes in patients admitted to hospital because of congestive heart failure (Abstract). Diabetes 50:A456, 2001
8. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987
9. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991
10. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303-310, 1991
11. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF, ATLAS Study Group: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100:2312-2318, 1999
12. Suskin N, McKelvie RS, Rouleau J, Sigouin C, Wiecek E, Yusuf S: Increased insulin and glucose levels in heart failure (HF). J Am Coll Cardiol 31:249A, 1998
13. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995
14. Factor SM, Minase T, Sonnenblick EH: Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 99:446-458, 1980
15. Bell DSH: Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 18 708-714, 1995
16. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS: Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 244:E528-E535, 1983
17. Giacomelli F, Wiener J: Primary myocardial disease in the diabetic mouse: an ultrastructural study. Lab Invest 40:460-473, 1979
18. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5-10, 2001
19. Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B: Myocardial composition and function in diabetes: the effects of chronic insulin use. Circ Res 49:1268-1277, 1981
20. Dash H, Johnson RA, Dinsmore RE, Francis CK, Harthorne JW: Cardiomyopathic syndrome due to coronary artery disease. II. Increased prevalence in patients with diabetes mellitus: a matched pair analysis. Br Heart J 39:740-747, 1977
21. Stone PN, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T: The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis: the MILIS Study Group. J Am Coll Cardiol 14:49-57, 1989
22. Genda A, Mizuno S, Nunoda S, Nakayama A, Igarashi Y, Sugihara N, Namura M, Takeda R, Buriko H, Hisada K: Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. Clin Cardiol 9:375-382, 1986
23. Ahmed SS, Jaferi GA, Narang RM, Regan TJ: Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J 89:153-158, 1975
24. Factor SM, van Horeven KH, Cho S, Fein FS: Microangiopathy and focal myocardial injury: their role in the development of diabetic cardiomyopathy. In The Diabetic Heart. Nagano M, Dhalla NS, Eds. New York, Raven Press, 1991, p. 89-101
25. Yarom R, Zirkin H, Stammler G, Rose AG: Human coronary microvessels in diabetes and ischaemia: morphometric study of autopsy material. J Pathol 166:265-270, 1992
26. Bristow MR: Why does the myocardium fail? Insights from basic science. Lancet 352 (Suppl. 1):S18-S114, 1998
27. Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 94:2285-2296, 1996
28. Heyliger CE, Pierce GN, Singal PK, Beamish RE, Dhalla NS: Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res Cardiol 77:610-618, 1982
29. Rupp H, Elimban V, Dhalla NS: Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Mol Cell Biochem 132:69-80, 1994
30. Dillmann WH: Diabetes mellitus and hypothyroidism induce changes in myosin isoenzyme distribution in the rat heart. Do alterations in fuel flux mediate these changes? Adv Exp Med Biol 194:469-479, 1986
31. Lopachuk G: Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 139:S115-S119, 2000
32. Panchal AR, Stanley WC, Kerner J, Sabbah HN: Beta-receptor blockade decreases camitine palmitoyl transferase 1 activity in dogs with heart failure. J Card Fail 4:121-126, 1998
33. Bristow M: Etomoxir: a new approach to treatment of chronic heart failure. Lancet 356:1621-1622, 2000
34. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Roden RL, Bristow MR: Beta-blocker-related improvement in ventricular function is associated with increased gene expression of SR CA2 + AT-Pase [894-5] (Abstract). J Am Coll Cardiol 33 (Suppl. A):216A, 1999
35. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR: Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365, 2002
36. Lowes BD, Abraham WT, Minobe WA, Gilbert EM, Roden RL, Bristow MR: Dynamic changes in the expression of contractility-regulating genes in the failing human heart associated with improvement or deterioration in ventricular systolic function [1899] (Abstract). Circulation 98 (Suppl. 1):1-361, 1998
37. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350:829-833, 1997
38. Stone PH, Raabe DS, Jaffe AS, Gustafson N, Muller JE, Turi ZG, Rutherford JD, Poole WK, Passamani E, Willerson JT: Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 11:453-463, 1988
39. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 275:1557-1562, 1996
40. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38:2101-2113, 2001
41. Joint National Committee on Prevention DEaToHBP: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
42. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV: Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668-2673, 2001
43. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
44. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, Lense L, Wachspress J: The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 77:607-612, 1988
45. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M: Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction: SOLVD Investigators. JAMA 270:1702-1707, 1993
46. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S: Natural history and patterns of current practice in heart failure: the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 22:14A-19A, 1993
47. Struthers AD, Morris AD: Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430-1432, 2002
48. Lainchbury JG, Redfield MM: Doppler echocardiographic-guided diagnosis and therapy of heart failure. Curr Cardiol Rep 1:55-66, 1999
49. McKenna K, Smith D, Tormey W, Thompson CJ: Acute hyperglycaemia causes elevation in plasma atrial natriuretic peptide concentrations in type 1 diabetes mellitus. Diabet Med 17:512-517, 2000
50. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Biochemical detection of left-ventricular systolic dysfunction. Lancet 351:9-13, 1998
51. Solang L, Malmberg K, Ryden L: Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J 20:789-795, 1999
52. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, de Marco T, Chatterjee K: Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23:1617-1624, 1994
53. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512-1515, 1997
54. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction: DIGAMI (Diabetes Insulin-Glucose in Acute Myocardial Infarction) Study Group. Eur Heart J 17:1337-1344, 1996
55. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784-1789, 2000
56. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343:155-158, 1994
57. Mjos OD: Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 50:1386-1389, 1971
58. Paolisso G, Manzella D, Rizzo MR, Ragno E, Barbieri M, Varricchio G, Varricchio M: Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 72:723-730, 2000
59. Baron AD, Brechtel G: Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 265: E61-E67, 1993
60. Nestler JE, Barlascini CO, Tetrault GA, Fratkin MJ, Clore JN, Blackard WG: increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia. Diabetes 39:1212-1217, 1990
61. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldo S, Van Obberghen S: Insulin but not IGF-1 stimulates VEGF mRNA expression via a P-3-kinase/PKB dependent pathway (Abstract). Diabetes 49 (Suppl. 1):A332, 2000
62. Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T: The oral insulin sensitizer, thiazolidinedione increases plasma vascular endothelial growth factor in type 2 diabetic patients (Letter). Diabetes Care 24:953-954, 2001
63. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M: Comparative actions of insulin sensitizers on ion channds in vascular smooth muscle. Eur J Pharmacol 423:1-7, 2001
64. Ferri C, Bellini C, Desideri G, De Mattia G, Santucci A: Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 19:505-506, 1996
65. Tack CJ, Lenders JW, Willemsen JJ, van Druten JA, Thien T, Lutterman JA, Smits P. Insulin stimulates epinephrine release under euglycemic conditions in humans. Metabolism 47:243-249, 1998
66. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
67. Tang WH, Young JB: Cardiomyopathy and heart failure in diabetes. Endocrinol Metab Clin North Am 30:1031-1046, 2001
68. Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K: Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158:113-119, 2001
69. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16:179-192, 1999
70. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865, 1991
71. Aceto JF, Baker KM: [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 258:H806-H813, 1990
72. Linz W, Scholkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 11:1325-1350, 1989
73. Katz AM: The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 121:363-371, 1994
74. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
75. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001
76. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators [published errata appear in N Engl J Med 342:748, 2000 and 342:1376, 2000]. N Engl J Med 342:145-153, 2000
77. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA: Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 19:1136-1144, 1992
78. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 337:872-876, 1991
79. Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, Farnham DJ, Randall OS, Dinh H, Arnold JM: Uniformity of captopril benefit in the SAVE Study: subgroup analysis: Survival and Ventricular Enlargement Study. Eur Heart J 15 (Suppl. B):2-8, 1994
80. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96:4239-4245, 1997
81. Haft JI: Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 17:73-86, 1974
82. Mann DL, Kent RL, Parsons B, Cooper G: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85:790-804, 1992
83. Festa A, D'Agostino R Jr, Hales CN, Mykkanen L, Haffner SM: Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care 23:624-628, 2000
84. Gavras H, Kremer D, Brown JJ, Gray B, Lever AF, MacAdam RF, Medina A, Morton JJ, Robertson JI: Angiotensin and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 89:321-332, 1975
85. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 69:1185-1195, 1991
86. Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000
87. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ: The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 21:I3-I13, 1998
88. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM: Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83:1201-1205, 1999
89. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 25:1225-1231, 1995
90. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D.: Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 17:1373-1381, 1991
91. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyoparhy (MDC) Trial Study Group. Lancet 342:1441-1446, 1993
92. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996
93. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
94. Smith SC, Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA: AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients With atherosclerotic cardiovascular disease, 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104:1577-1579, 2001
95. Evans JM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort study. BMJ 324:1357-1361, 2002
96. Bell DSH, Yumuk V: Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract 3:281-283, 1997
97. Bell DS: Beta adrenergic blocking agents in patients with diabetes: friend and foe. Endocr Pract 5:51-53, 1999
98. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 126:955-959, 1997